Stock listing
NASDAQ:NVNO enVVeno Medical Corporation Stock
Home listing (NASDAQ) of enVVeno Medical Corporation
Follow enVVeno Medical Corporation into a list and get an email when it puts out news.
Share price · NASDAQ:NVNO
$5.25 USD -0.52 (-9.0%)
Close on Nov 20, 2026
- Day range
- $5.22 – $5.76 USDNov 20, 2026
- Volume
- 10,355 sharesNov 20, 2026
- Market cap
- $3.65M USDAt the close on Nov 20, 2026 · price × 694,826 shares outstanding
- 52-week range
- $5.22 – $14.67 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $247,262 USDMedian day 19,183 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NVNO · Home | $5.25 USD | -0.52 (-9.0%) | 10,355 | $5.53 | $5.76 | $5.22 | $5.77 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVNO · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.25 | -0.52 | -9.0% | $5.53 | $5.76 | $5.22 | 10,355 | |
| $5.77 | 0.00 | 0.0% | $5.77 | $6.30 | $5.53 | 18,048 | |
| $5.77 | -0.175 | -2.9% | $6.037 | $6.19 | $5.695 | 11,056 | |
| $5.945 | -0.225 | -3.6% | $6.50 | $6.50 | $5.80 | 12,092 | |
| $6.17 | -0.405 | -6.2% | $6.63 | $6.63 | $6.14 | 7,516 | |
| $6.575 | +0.055 | +0.8% | $6.42 | $6.575 | $6.414 | 4,235 | |
| $6.52 | +0.07 | +1.1% | $6.96 | $7.562 | $6.45 | 5,827 | |
| $6.45 | -0.40 | -5.8% | $6.80 | $6.80 | $6.365 | 10,958 | |
| $6.85 | +0.12 | +1.8% | $6.73 | $7.17 | $6.62 | 14,977 | |
| $6.73 | -0.24 | -3.4% | $7.04 | $7.214 | $6.31 | 26,747 | |
| $6.97 | -0.03 | -0.4% | $7.23 | $7.37 | $6.79 | 22,346 | |
| $7.001 | -0.175 | -2.4% | $7.17 | $7.741 | $6.995 | 63,619 | |
| $7.175 | +0.305 | +4.4% | $7.15 | $7.61 | $6.91 | 106,309 | |
| $6.87 | +0.14 | +2.1% | $6.78 | $7.26 | $6.78 | 57,414 | |
| $6.73 | -0.29 | -4.1% | $6.87 | $7.11 | $6.70 | 19,183 | |
| $7.02 | +0.275 | +4.1% | $6.89 | $7.34 | $6.872 | 14,438 | |
| $6.745 | +0.005 | +0.1% | $7.195 | $7.195 | $6.715 | 45,302 | |
| $6.74 | +0.03 | +0.4% | $6.75 | $6.96 | $6.61 | 69,569 | |
| $6.71 | +0.06 | +0.9% | $6.57 | $6.725 | $6.56 | 3,773 | |
| $6.65 | -0.26 | -3.8% | $6.72 | $6.76 | $6.55 | 7,900 | |
| $6.91 | -0.42 | -5.7% | $7.30 | $7.57 | $6.601 | 30,100 | |
| $7.33 | -0.37 | -4.8% | $8.27 | $8.27 | $7.20 | 45,700 | |
| $7.70 | +0.01 | +0.1% | $8.45 | $8.45 | $7.52 | 104,200 | |
| $7.69 | +0.22 | +2.9% | $7.995 | $8.155 | $7.525 | 33,200 | |
| $7.47 | -0.455 | -5.7% | $8.01 | $8.01 | $7.30 | 67,600 | |
| $7.925 | +0.525 | +7.1% | $7.27 | $7.925 | $7.27 | 41,800 | |
| $7.40 | -0.57 | -7.2% | $8.00 | $8.13 | $7.18 | 18,900 | |
| $7.97 | -0.18 | -2.2% | $8.65 | $8.65 | $7.60 | 48,600 | |
| $8.15 | -0.60 | -6.9% | $8.80 | $8.80 | $8.06 | 122,900 | |
| $8.75 | +0.575 | +7.0% | $8.41 | $9.58 | $8.41 | 36,500 | |
| $8.175 | -0.225 | -2.7% | $8.41 | $8.475 | $8.06 | 6,700 | |
| $8.40 | +0.20 | +2.4% | $7.98 | $8.43 | $7.91 | 15,100 | |
| $8.20 | +0.19 | +2.4% | $8.01 | $8.47 | $7.96 | 36,800 | |
| $8.01 | -0.09 | -1.1% | $7.92 | $8.60 | $7.75 | 10,600 | |
| $8.10 | +0.06 | +0.7% | $8.11 | $8.78 | $7.70 | 24,300 | |
| $8.04 | +0.24 | +3.1% | $8.82 | $9.41 | $8.01 | 25,200 | |
| $7.80 | -0.825 | -9.6% | $8.53 | $9.00 | $7.80 | 122,400 | |
| $8.625 | -0.185 | -2.1% | $8.74 | $8.74 | $8.624 | 2,100 | |
| $8.81 | +0.14 | +1.6% | $8.81 | $8.81 | $8.81 | 1,000 | |
| $8.67 | -0.42 | -4.6% | $8.67 | $8.67 | $8.67 | 400 | |
| $9.09 | +0.13 | +1.5% | $8.61 | $9.09 | $8.61 | 700 | |
| $8.96 | -0.14 | -1.5% | $8.845 | $8.96 | $8.66 | 4,500 | |
| $9.10 | +0.05 | +0.6% | $8.91 | $9.11 | $8.86 | 10,000 | |
| $9.05 | +0.075 | +0.8% | $8.84 | $9.157 | $8.59 | 25,100 | |
| $8.975 | +0.182 | +2.1% | $8.95 | $9.155 | $8.645 | 7,900 | |
| $8.793 | -0.257 | -2.8% | $9.19 | $9.44 | $8.78 | 4,500 | |
| $9.05 | -0.27 | -2.9% | $9.416 | $9.44 | $7.01 | 39,300 | |
| $9.32 | -0.06 | -0.6% | $9.60 | $9.60 | $9.07 | 30,000 | |
| $9.38 | -1.11 | -10.6% | $10.24 | $10.32 | $9.28 | 90,900 | |
| $10.49 | -0.63 | -5.7% | $11.49 | $11.65 | $9.97 | 55,600 | |
| $11.12 | +0.02 | +0.2% | $11.38 | $11.68 | $11.10 | 60,900 | |
| $11.10 | -0.39 | -3.4% | $11.41 | $11.82 | $10.85 | 94,400 | |
| $11.49 | +0.051 | +0.4% | $11.31 | $11.62 | $11.16 | 4,200 | |
| $11.44 | +0.339 | +3.1% | $11.05 | $11.44 | $11.05 | 2,100 | |
| $11.10 | -0.20 | -1.8% | $11.42 | $11.42 | $11.00 | 2,400 | |
| $11.30 | +0.32 | +2.9% | $11.44 | $11.55 | $11.21 | 4,800 | |
| $10.98 | -0.49 | -4.3% | $11.36 | $11.36 | $10.53 | 42,200 | |
| $11.47 | +0.72 | +6.7% | $10.51 | $11.47 | $10.26 | 24,900 | |
| $10.75 | -0.49 | -4.4% | $10.80 | $10.80 | $10.67 | 3,200 | |
| $11.24 | -0.228 | -2.0% | $11.53 | $11.94 | $11.20 | 6,900 | |
| $11.47 | +0.668 | +6.2% | $11.30 | $11.95 | $10.81 | 17,300 | |
| $10.80 | +0.45 | +4.3% | $10.70 | $11.17 | $10.34 | 3,876 | |
| $10.35 | +0.06 | +0.6% | $10.59 | $11.41 | $10.30 | 20,281 | |
| $10.29 | -0.10 | -1.0% | $10.78 | $11.15 | $10.13 | 21,200 | |
| $10.39 | -0.09 | -0.9% | $10.44 | $11.59 | $10.17 | 26,900 |
Splits
2 splits since 2020 · NASDAQ:NVNO · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-35 | Consolidation | |
| 1-for-25 | Consolidation |
- Ticker
- NASDAQ:NVNO
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 20, 2026
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
Latest deck · Jul 14, 2026
Investor Presentation (July 2026)
Investor deck · 25 slides
Latest news
enVVeno Medical Presents Three-Year Surgical Venous Valve Replacement Data Showing Sustained Clinical Benefit and Highlights Next-Generation enVVe Transcatheter System at the 53rd Annual VEITH Symposium
Nov 20, 2026
Closed $5.25 (-9.0%) on Nov 20, 2026
enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium
Nov 2, 2026
Closed $6.87 (+2.1%) on Nov 2, 2026
enVVeno Medical Reports Third Quarter 2026 Financial Results and Prepares to Treat First Patients in FDA-Approved TAVVE Pivotal Study
Oct 30, 2026
Closed $6.73 (-4.1%) on Oct 30, 2026
enVVeno Medical Releases New Episode of "WTF" Video Series Featuring CEO Rob Berman
Oct 21, 2026
Closed $7.33 (-4.8%) on Oct 21, 2026
enVVeno Medical CEO Rob Berman Goes Direct to Investors with New "WTF" Video Series
Sep 16, 2026
Closed $9.05 (-2.9%) on Sep 16, 2026
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
Sep 11, 2026
Closed $10.49 (-5.7%) on Sep 11, 2026
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Jul 31, 2026
Closed $10.60 (-0.2%) on Jul 31, 2026
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
Jul 7, 2026
Closed $11.02 (-0.7%) on Jul 7, 2026
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
Jun 22, 2026
Closed $10.50 (+5.0%) on Jun 22, 2026
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Jun 2, 2026
Closed $10.75 (+0.7%) on Jun 2, 2026
enVVeno Medical Corporation on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 17 in the last 12 months · 86 in all · newest Nov 20, 2026 · oldest 2021
- Decks
- 4 decks · latest Jul 14, 2026
Where enVVeno Medical Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NVNO · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NVNO | BOATS | United States | USD |
| Frankfurt:5HJ0 | Frankfurt | Germany | EUR |
| Lang & Schwarz:A42085 | Lang & Schwarz | Germany | EUR |
| LS Exchange:A42085 | LS Exchange | Germany | EUR |
Valuation
Price/book 0.2× against a median of 0.5×: 5th lowest of 11 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$14.82M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.2×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.12
Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| enVVeno Medical Corporation · NASDAQ:NVNO | US$3.65M | −US$14.82M | n/a | n/a | n/a | 0.2× | n/a | 0.0× | 1.12 |
| Regentis Biomaterials Ltd. · AMEX:RGNT | US$5.05M | −US$3.90M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| SeaStar Medical Holding Corporation · NASDAQ:ICU | US$4.97M | US$981,429 | n/a | 0.5× | n/a | 10.6× | −678.2% | 0.0× | 1.44 |
| WORK Medical Technology Group LTD · NASDAQ:WOK | US$4.84M | US$8.21M | n/a | 0.8× | n/a | 0.2× | −10.9% | 0.2× | 2.76 |
| Kelyniam Global, Inc. · OTC:KLYG | US$4.56M | US$4.84M | n/a | 1.4× | 31.9× | 6.6× | −6.0% | 0.6× | 1.15 |
| Meihua International Medical Technologies Co., Ltd. · OTC:MHUAF | US$4.53M | −US$1.63M | 0.7× | −0.0× | −0.2× | 0.0× | 11.0% | 0.1× | 0.62 |
| Aurora Spine Corp. · TSXV:ASG | US$4.36M | US$6.91M | n/a | 0.4× | 45.6× | 1.5× | −7.0% | 1.0× | -0.13 |
| IceCure Medical Ltd. · NASDAQ:ICCM | US$3.71M | −US$3.80M | n/a | −1.0× | n/a | 0.4× | −439.7% | 0.1× | 1.98 |
| Spineway SA · EURONEXT:ALSPW | US$3.63M | US$1.46M | n/a | 0.1× | n/a | 0.1× | −18.0% | 0.1× | n/a |
| Baird Medical Investment Holdings Ltd · NASDAQ:BDMD | US$2.88M | US$16.81M | n/a | 0.8× | n/a | 0.1× | −121.0% | 0.4× | -0.13 |
| ScandiDos AB · OMXSTO:SDOS | US$2.84M | US$1.51M | n/a | 0.3× | n/a | 0.6× | −16.4% | 0.1× | n/a |
| Median of the others | US$4.45M | US$1.49M | 0.7× | 0.4× | 31.9× | 0.5× | −16.4% | 0.1× | 1.30 |
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 30.00 USD · Analysts' mean
- EPS, year to Dec 2026
- -16.19 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Robert Berman | Chief Executive Officer and Director |
| Jennifer Bright | Chief Financial Officer |
| Avi Sharma | Senior Vice President, Clinical, Regulatory and Quality |
| Hamed Alavi | Senior Vice President and Chief Technology Officer |
| Marc Glickman | Senior Vice President and Chief Medical Officer |
| Sandy Prietto | Vice President, Marketing |
Board
| Director | Role |
|---|---|
| Francis Duhay | Director |
| Matthew Jenusaitis | Director |
| Robert Berman | Chief Executive Officer and Director |
| Robert Gray | Director |
| Sanjay Shrivastava | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Oct 29, 2026 · After close | −4.1% |
| Q2 2026 | Jul 30, 2026 · After close | −0.2% |
| Q1 2026 | May 6, 2026 · After close | +1.5% |
| Q4 2025 | Feb 26, 2026 | −3.4% |
| Q3 2025 | Nov 28, 2025 | +17.1% |
| Q2 2025 | Jul 31, 2025 · After close | +5.6% |
| Q1 2025 | May 6, 2025 · After close | +8.0% |
| Q4 2024 | Feb 28, 2025 · Before open | −9.9% |
| Q3 2024 | Oct 31, 2024 · Before open | +1.8% |
| Q2 2024 | Jul 31, 2024 · After close | −0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −2.5% |
| Q4 2023 | Feb 29, 2024 · After close | +3.9% |
| Q3 2023 | Oct 26, 2023 · Before open | −2.5% |
| Q2 2023 | Jul 31, 2023 · After close | +5.3% |
| Q1 2023 | Apr 28, 2023 · After close | −1.9% |
| Q4 2022 | Mar 2, 2023 · After close | −2.2% |
| Q3 2022 | Oct 27, 2022 · After close | +1.3% |
| Q2 2022 | Aug 3, 2022 · After close | +8.5% |
| Q1 2022 | Apr 29, 2022 · After close | +2.0% |
| Q4 2021 | Mar 28, 2022 · Before open | +26.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 25 slides | Jul 14, 2026 |
| VEITH Symposium 2024 | Conference | 65 slides | November 2024 |
| Hancock Jaffe Laboratories — 10th Indonesian Vascular Conference (October 2019) | Conference | 14 slides | Oct 25, 2019 |
| Hancock Jaffe Laboratories — Technical Presentation (July 2019) | Technical | 23 slides | Jul 26, 2019 |
IPO
Went public as Hancock Jaffe Laboratories, Inc. Final prospectus filed on Jun 1, 2018.
- Price range
- US$6.00 to US$8.00 a unit
- Units offered
- 1,142,857 units
- Offering size
- US$6.9 million to US$9.1 million · Units offered times the price range, worked out by 6ix
- Underwriters' option
- Up to 171,429 more units
- Listing
- HJLI on the Nasdaq Capital Market · Has applied to list
- Underwriter
- Network 1 Financial Securities
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 13, 2017 |
| Filed publicly | Sep 7, 2017 |
| Amended 8 times | Newest May 30, 2018 |
| Shares registered with an exchange | Dec 12, 2017 |
| Declared effective by the SEC | May 30, 2018 |
| Final prospectus, with the price | Jun 1, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jun 1, 2018 |
| S-1MEF · Registration of more shares for the same offering | May 31, 2018 |
| EFFECT · Notice that a registration is effective | May 30, 2018 |
| CERT · Exchange's certificate of listing | May 30, 2018 |
| S-1/A · Registration statement, amended | May 30, 2018 |
| 8-A12B/A · Registration of shares for listing on an exchange, amended | May 25, 2018 |
| CORRESP · Letter to the SEC | May 25, 2018 |
| CORRESP · Letter to the SEC | May 25, 2018 |
| S-1/A · Registration statement, amended | May 22, 2018 |
| S-1/A · Registration statement, amended | May 14, 2018 |
All 34 filings
Open IPO · From the cover of the amended prospectus (S-1/A) filed May 22, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 31.2K | 186.6K | 422.1K | ||||||
| Cost of revenue | 419.7K | ||||||||
| Gross profit | 186.6K | 2.45K | |||||||
| Research and development | 9.98M | 12.2M | 13.6M | 9.91M | 5.73M | 4.25M | 2.21M | 1.24M | 649.7K |
| Selling, general and administrative | 10.9M | 11.6M | 11.7M | 15.0M | 11.2M | 4.88M | 4.91M | 6.48M | 5.46M |
| Operating income | -20.9M | -23.8M | -25.2M | -24.9M | -16.9M | -9.14M | -7.68M | -7.85M | -6.10M |
| Depreciation and amortization | 136.0K | 189.0K | 220.0K | 212.0K | 149.0K | 97.5K | 123.7K | 133.4K | 139.2K |
| EBITDA | -20.8M | -23.6M | -25.0M | -24.7M | -16.7M | -9.04M | -7.55M | -7.72M | -5.96M |
| Interest expense | 305.5K | 172.8K | |||||||
| Income before tax | -19.5M | -21.8M | |||||||
| Net income | -19.5M | -21.8M | -23.5M | -24.7M | -16.5M | -9.14M | -7.63M | -13.0M | -7.79M |
| Earnings per share, basic | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | -7.54 | -12.10 | -1.75 | -1.35 |
| Earnings per share, diluted | -33.06 | -44.53 | -1.91 | -2.20 | -1.90 | -7.54 | -12.10 | -1.75 | -1.35 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.06M | 1.75M | 3.62M | 4.55M | 54.7M | 9.33M | 1.31M | 2.74M | 77.7K |
| Short-term investments | 25.1M | 41.4M | 42.8M | 34.5M | |||||
| Receivables | 32.0K | 35.2K | |||||||
| Current assets | 28.8M | 43.7M | 46.9M | 39.4M | 55.0M | 9.57M | 1.42M | 2.84M | 170.4K |
| Property, plant and equipment | 51.0K | 182.0K | 334.0K | 521.0K | 618.0K | 399.0K | 344.0K | 26.2K | 23.8K |
| Total assets | 29.6M | 45.0M | 48.6M | 41.7M | 57.7M | 10.5M | 3.43M | 3.56M | 2.21M |
| Accounts payable | 358.0K | 1.01M | 1.22M | 560.0K | 1.39M | 1.22M | 1.08M | 1.45M | |
| Current liabilities | 2.12M | 2.10M | 1.37M | 1.53M | 1.58M | 3.19M | 1.88M | 1.52M | |
| Total liabilities | 2.43M | 2.79M | 2.44M | 2.93M | 3.29M | 3.44M | 2.44M | 1.52M | 8.17M |
| Shareholders' equity | 27.1M | 42.2M | 46.2M | 38.7M | 54.4M | 7.10M | 989.9K | 2.04M | -11.1M |
| Shares outstanding | 656.0K | 501.0K | 13.3M | 9.47M | 9.47M | 2.54M | 717.3K | 11.7M | 6.13M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -15.6M | -16.8M | -18.9M | -15.6M | -11.8M | -7.68M | -5.90M | -6.36M | -4.20M |
| Capital spending | -5.00K | -37.0K | -33.0K | -115.0K | -368.0K | -180.3K | -363.9K | -12.4K | -10.9K |
| Free cash flow | -15.6M | -16.9M | -18.9M | -15.7M | -12.2M | -7.86M | -6.26M | -6.37M | -4.21M |
| Cash from investing | 15.9M | 1.33M | -7.87M | -34.6M | -368.0K | -180.3K | -363.9K | -12.4K | 165.3K |
| Cash from financing | 1.02M | 13.6M | 25.8M | 57.6M | 15.1M | 5.64M | 9.03M | 4.06M | |
| Change in cash | 1.31M | -1.87M | -935.0K | -50.2M | 45.4M | 7.22M | -623.4K | 2.66M | 21.2K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| DEFA14A · Additional proxy material | Oct 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 29, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Oct 29, 2026 | Quarterly report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 11, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Jul 30, 2026 | Quarterly report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Jul 14, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Apr 29, 2026 | Results | SEC |
| S-8 · Registration statement for employee plans | Mar 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 26, 2026 | Annual report | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 12, 2026 | Other filings | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 20, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 10, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 4, 2026 | Results | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Meeting outcome | SEC |
| DEFR14A | Dec 2, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 20, 2025 | Current report | SEC |
| PRER14A | Nov 19, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Current report | SEC |
| 8-K · Current report | Oct 30, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 30, 2025 | Offer document | SEC |
| DEFA14A · Additional proxy material | Oct 30, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 30, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Oct 10, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 15, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 9, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 20, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Jul 31, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 20, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Apr 30, 2025 | Quarterly report | SEC |
| 8-K · Current report | Apr 21, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Mar 17, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 14, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 12, 2025 | Offer document | SEC |
| S-3/A · Registration statement, amended | Mar 12, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 10, 2025 | Other filings | SEC |
| S-3 · Registration statement | Feb 28, 2025 | Offer document | SEC |
| 10-K/A · Annual report, amended | Feb 28, 2025 | Annual report | SEC |
| 10-K · Annual report | Feb 27, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 23, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2024 | Insider trade | SEC |
| DEF 14A · Proxy statement | Nov 19, 2024 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Sep 30, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 30, 2024 | Offer document | SEC |
| FWP · Free writing prospectus | Sep 26, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Sep 26, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 31, 2024 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Apr 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 6, 2024 | Current report | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 23, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Dec 7, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 7, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Nov 16, 2023 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Nov 6, 2023 | Other filings | SEC |
| DEF 14A · Proxy statement | Nov 3, 2023 | Meeting notice | SEC |
| CORRESP · Letter to the SEC | Nov 1, 2023 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 31, 2023 | Other filings | SEC |
| S-3 · Registration statement | Oct 26, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Oct 25, 2023 | Quarterly report | SEC |
| 8-K · Current report | Oct 12, 2023 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Aug 24, 2023 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 21, 2023 | Other filings | SEC |
| S-3/A · Registration statement, amended | Aug 14, 2023 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Aug 7, 2023 | Other filings | SEC |
| S-3 · Registration statement | Jul 31, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Jul 31, 2023 | Quarterly report | SEC |
| 25-NSE | May 26, 2023 | Other filings | SEC |
| 424B3 · Prospectus | May 5, 2023 | Offer document | SEC |
| 10-Q · Quarterly report | Apr 28, 2023 | Quarterly report | SEC |
| 10-K · Annual report | Mar 2, 2023 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 31, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 6, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2022 | Insider trade | SEC |
| DEF 14A · Proxy statement | Nov 1, 2022 | Meeting notice | SEC |
| 10-Q · Quarterly report | Oct 27, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Sep 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 3, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Jul 1, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 28, 2022 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | May 16, 2022 | Other filings | SEC |
| 10-Q/A · Quarterly report, amended | May 11, 2022 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | May 11, 2022 | Annual report | SEC |
| CORRESP · Letter to the SEC | May 11, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 6, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | Apr 29, 2022 | Quarterly report | SEC |
| S-8 · Registration statement for employee plans | Apr 18, 2022 | Offer document | SEC |
| 10-K · Annual report | Mar 28, 2022 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 11, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 19, 2022 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Dec 3, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Dec 2, 2021 | Insider trade | SEC |
| 8-K · Current report | Dec 1, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 19, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2021 | Quarterly report | SEC |
| DEF 14A · Proxy statement | Nov 1, 2021 | Meeting notice | SEC |
| 8-K · Current report | Oct 1, 2021 | Current report | SEC |
| 8-K · Current report | Sep 22, 2021 | Current report | SEC |
| SC 13G · Big-stake notice | Sep 17, 2021 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 15, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Sep 15, 2021 | Insider trade | SEC |
| 8-K · Current report | Sep 8, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Sep 8, 2021 | Offer document | SEC |
| 4 · Change in ownership | Aug 27, 2021 | Insider trade | SEC |
| 8-K · Current report | Aug 12, 2021 | Material contract | SEC |
| 424B5 · Prospectus | Aug 12, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 10, 2021 | Quarterly report | SEC |
| 424B3 · Prospectus | Aug 6, 2021 | Offer document | SEC |
| 4 · Change in ownership | Jun 21, 2021 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 26, 2021 | Offer document | SEC |
| 4 · Change in ownership | May 25, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2021 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | May 12, 2021 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | May 7, 2021 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Apr 30, 2021 | Offer document | SEC |
| 10-K · Annual report | Mar 31, 2021 | Annual report | SEC |
| 8-K · Current report | Feb 24, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Feb 23, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 23, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2021 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 19, 2021 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 17, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Feb 12, 2021 | Material contract | SEC |
| 424B4 · Prospectus | Feb 9, 2021 | Offer document | SEC |
This page holds 200 of 416 filings. Open Filings
Cap table
Built by 6ix from enVVeno Medical Corporation’s releases · as of Oct 27, 2026
- Common shares
- 694,826
- Fully diluted
- 694,826
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 694,826 | Oct 27, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 27, 2026 | 694,826 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Steven Girgenti Other companies: bioAffinity Technologies, Inc. (Executive Chairman, Director · Aug 29, 2022 – Jan 10, 2025 · Past); Vycor Medical Inc. (Director · Mar 11, 2014 – Apr 1, 2021 · Past) | Director · May 30, 2018 – May 30, 2018 · Past |
| Robert Berman Other companies: Anixa Biosciences, Inc. (President & CEO, Director · Jul 1, 2013 – Jun 2, 2017 · Past) | Chief Executive Officer and Director · Since at least May 30, 2018 |
| William R Abbott Other companies: Astrana Health Inc. (VP Finance & Corp. Controller · Sep 20, 2015 – Sep 20, 2015 · Past) | See Remarks. · May 30, 2018 – May 30, 2018 · Past |
| Avi Sharma | Senior Vice President, Clinical, Regulatory and Quality · Since at least Nov 5, 2026 |
| Craig Glynn | Chief Financial Officer · Apr 6, 2020 – Dec 5, 2023 · Past |
| Francis Duhay | Director · Since at least Aug 16, 2022 |
| Hamed Alavi | Chief Technology Officer · Since at least Dec 16, 2025 |
| Jennifer Bright | Chief Financial Officer · Since at least May 19, 2025 |
| Marc Glickman | Senior Vice President and Chief Medical Officer · Since at least May 30, 2018 |
| Matthew Jenusaitis | Director · Since at least Oct 21, 2020 |
All 15 people
| Person | Seat |
|---|---|
| Robert A Rankin | Chief Financial Officer · Jul 16, 2018 – Jul 16, 2018 · Past |
| Robert Gray | Director · Since at least Dec 5, 2023 |
| Sandy Prietto | Vice President, Marketing · Since at least Nov 4, 2026 |
| Sanjay Shrivastava | Director · Since at least Oct 2, 2018 |
| Susan Montoya | See Remarks · May 30, 2018 – May 30, 2018 · Past |
Log in to ask 6ix AI your own questions about enVVeno Medical Corporation.